Ultragenyx Pharmaceutical Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-575.0M | $-569.0M | $-607.0M | $-707.4M | $-454.0M | $-186.6M | $-402.7M | $-197.6M |
| Depreciation & Amortization | $35.0M | $36.0M | $26.0M | $18.2M | $13.2M | $12.3M | $8.5M | $19.5M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — | — | — | — |
| Net Cash from Operating Activities | $-466.0M | $-414.0M | $-475.0M | $-380.5M | $-338.7M | $-132.2M | $-345.4M | $-290.6M |
| Investing Activities | ||||||||
| Capital Expenditures | $6.0M | $7.0M | $44.0M | $116.1M | $73.1M | $43.9M | $24.8M | $4.1M |
| Business Acquisitions | — | $0 | $0 | $75.0M | $0 | $0 | — | — |
| Net Cash from Investing Activities | $236.0M | $-18.0M | $168.0M | $-291.7M | $-195.4M | $-179.1M | $-13.0M | $-33.3M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $478.0M | $399.0M | $388.0M | $501.2M | $118.6M | $600.3M | $679.3M | $336.9M |
| Net Change in Cash | $252.0M | $-35.0M | $81.0M | $-172.0M | $-416.7M | $290.1M | $320.7M | $12.5M |
| Free Cash Flow | $-472.0M | $-421.0M | $-519.0M | $-496.6M | $-411.8M | $-176.1M | $-370.2M | $-294.6M |